|
|
Post by peppy on Jul 7, 2018 15:05:16 GMT -5
So the guy who knows the product better than anyone, has uncovered all this great data, and is seemingly the one that is supposed to lead the journey to SOC doesn't buy shares with his own money when he said he would. Wouldn't he be pouring in money hand over fist if he thought that the opportunity was so great with "veins of gold" flowing in all directions? Either he... 1) Doesn't believe in Afrezza as much as this board claims he does (unlikely) 2) Knows the process will be longer than we all would like and not a slam-dunk like many are hoping with more dilution (can buy in later if he chooses at a lower price, no hurry) It's not a great signal either way for investors. You can talk all day about how great everything is. I prefer those who lead by example. That means nothing to me, but maybe it does to someone out there.  The universities these people work for have endocrinology departments and clinics. Let's see Elizabeth R Seaquist write in Minnesota. United Health. 31% less hypoglycemia. |
|
|
|
Post by goyocafe on Sept 16, 2018 12:40:35 GMT -5
With the STAT results now “published” and pier reviewed, will the ADA have any more compulsion to at least make note of the reduced hypos offered by Afrezza? Would love to see their new and improved “living SOC” process fulfill its vision.
|
|
